Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic HSCT for VEXAS Syndrome
NCT05027945Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2023
- Primary completion
- Jul 2031
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic hematopoietic stem cells in VEXAS syndrome (VEXAS), sponsored by National Cancer Institute. Started Feb 2023; status: recruiting.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
VEXAS syndrome (VEXAS)
Beyond the preview
Go deeper on NCT05027945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027945.